First-line treatment of chronic hepatitis B with entecavir or tenofovir in `real-life' settings: from clinical trials to clinical practice
Journal of Viral Hepatitis, 05/18/2012Pol S et al.
Two real–life studies of TDF reported response rates of 71–92% after up to 21 months of treatment. Low incidences of drug resistance and favourable tolerabilities were reported for both drugs, thus confirming the results from registration trials.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.